chronic idiopathic urticaria

Updated: December 2, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

omalizumab

150 - 375

Subcutaneous (SC)

every 2-4 weeks

fexofenadine hydrochloride

60 mg 2 times a day or 180 mg per day with water
A 60 mg dosage is recommended as an initial dosage in patient who have reduced renal function

omalizumab

<12 years: Safety and efficacy not established
≥12 years: 150-300mg subcutaneous every four weeks

fexofenadine

<6 months: Not recommended for usage
Six months to 2 years: 15mg orally twice a day
Two years to 12 years: 30mg orally twice a day
>12 years: 60mg orally twice a day or 180mg orally every day

Allegra ODT:
Six years to 12 years: 30mg orally twice a day

6 years to 11 years: 30 mg 2 times a day with water
A 30 mg dosage is recommended as an initial dosage in pediatric patient who have reduced renal function

Future Trends